Paige Britt is an assistant editor for Targeted Oncology covering gyencologic cancers and lyphomas. Contact her at pbritt@targetedonc.com.
The ROSELLA trial reveals relacorilant plus nab-paclitaxel significantly improves survival in platinum-resistant ovarian cancer without increasing safety risks.
Cervical cancer treatment evolves with molecular screening and immunotherapies, emphasizing early detection as key to improving patient outcomes.
New cancer vaccine MVP-S shows promising results in recurrent ovarian cancer, enhancing immune response and improving treatment outcomes with pembrolizumab.
A groundbreaking trial reveals the promising efficacy of fruquintinib and sintilimab for advanced endometrial cancer, offering new hope for patients.
The FDA designates soficabtagene geleucel as a breakthrough therapy, highlighting its potential in treating relapsed T cell leukemia and lymphoma.
Sofetabart mipitecan receives FDA breakthrough therapy designation, showing promising efficacy in treating platinum-resistant ovarian cancer.
Early findings from the QUILT-106 trial reveal promising outcomes for CD19 CAR-NK cell therapy combined with rituximab in treating Waldenstrom lymphoma.
Epcoritamab shows promising results in improving progression-free survival for patients with relapsed/refractory DLBCL, paving the way for future therapies.
Nivolumab plus AVD shows significant improvement in progression-free survival for advanced Hodgkin lymphoma, establishing it as a preferred treatment option.
Spatial transcriptome sequencing uncovers distinct tumor microenvironment subtypes in angioimmunoblastic T-cell lymphoma, enhancing patient stratification and immunotherapy strategies.
The SCORES trial reveals suvemcitug significantly enhances survival and disease control in patients with platinum-resistant recurrent ovarian cancer.
A systematic review reveals PARP inhibitors improve progression-free survival in advanced ovarian cancer but lack overall survival benefits, highlighting treatment variability.
ZUMA-14 trial reveals promising efficacy and safety of axi-cel and rituximab combination therapy for refractory large B-cell lymphoma patients.
Experts explore evolving treatment strategies for head and neck squamous cell carcinoma, emphasizing biomarker analysis and the importance of evidence-based guidelines.
Novel small molecule inhibitors show promising efficacy in endometrial cancer, with ongoing trials expanding treatment options for challenging patient populations.
FDA meeting guides Plus Therapeutics in advancing rhenium Re 186 obisbemeda for leptomeningeal metastases, paving the way for pivotal trials.
A groundbreaking blood test for colorectal cancer shows enhanced sensitivity, promising earlier detection and improved patient outcomes in upcoming studies.
Atossa Therapeutics advances Z-endoxifen for metastatic breast cancer, showing promise in clinical trials and receiving FDA approval to proceed with studies.
A recent analysis highlights the efficacy of melphalan/HDS for metastatic uveal melanoma, showing improved outcomes in patients with lower hepatic tumor burden.
A phase 2 study reveals that combining brentuximab vedotin with gemcitabine shows promising efficacy and safety for relapsed peripheral T-cell lymphoma patients.
New research reveals that combining midostaurin with standard chemotherapy significantly improves survival rates and reduces minimal residual disease in AML patients.
A phase 2 trial shows ribociclib and letrozole effectively treat recurrent low-grade serous carcinoma, achieving significant response rates and durable control.
A groundbreaking study reveals that ultrasensitive ctDNA assays significantly enhance prognosis for large B-cell lymphoma, outperforming traditional PET assessments.
Research uncovers distinct sex-based differences in exosomal ncRNA dysregulation in multiple myeloma, highlighting the need for personalized treatment strategies.
Hematologic oncology sees breakthroughs in treatment efficacy and regulatory challenges, highlighting advancements in BTK degraders and essential thrombocythemia therapies.
Discover groundbreaking advancements in urologic oncology, including new standards for prostate, kidney, and bladder cancer treatments that enhance patient outcomes.
FDA approves mosunetuzumab-axgb for quick subcutaneous treatment of relapsed follicular lymphoma, enhancing patient care and reducing clinic time.
Pirtobrutinib shows significant efficacy and safety in treating relapsed/refractory follicular lymphoma, with promising response rates and durable outcomes.
FDA approves CBI-1214 for colorectal cancer, enabling fast-tracked clinical trials and highlighting innovative T-cell engager technology.